Amer Zeidan: Nice paper from MD Anderson Cancer Centre group on CPX-351 for HR MDS

Amer Zeidan shared on X/Twitter:

“Nice paper from MD Anderson Cancer Centre group on CPX-351 for HR MDS. They show International Working Group 2023 response criteria more clinically meaningful than 2006 criteria ‘Per 2023 criteria, most mCRs were unilineage (26%) or bilineage (26%) CR with limited count recovery (CRL)’.”

For the article click here.
Source: Amer Zeidan/Twitter

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.